ライフサイエンスコーパス: valve

1 459 in each group with BE or self-expanding valves).

2 driven changes in diameter upstream from the valve.

3 erwent attempted TPVR with a Sapien XT or S3 valve.

4 the blood pool, pulmonary veins, and mitral valve.

5 underwent TPVR with either a Sapien XT or S3 valve.

6 ients receiving a 29-mm (39%) or 26-mm (34%) valve.

7 elopment and maintenance of lymphatic vessel valves.

8 ses were performed in human tricuspid aortic valves.

9 sis, is upregulated in human calcific aortic valves.

10 aortic side of leaflets of explanted aortic valves.

11 advantages over other commercially available valves.

12 similar durability as surgical bioprosthetic valves.

13 was unrelated to AF and inserted mechanical valves.

14 ession of calcium volume score in the aortic valve (14% [95% CI, 5-24] versus 98% [95% CI, 77-123]; P

15 uals with Marfan syndrome or bicuspid aortic valve, a family history of AD was associated with an RR

16 ity) were evaluated and defined according to Valve Academic Research Consortium-2 criteria.

17 Valve Academic Research Consortium-2 device success was

18 ocedural characteristics were collected, and Valve Academic Research Consortium-2 outcomes were repor

19 The rates of Mitral Valve Academic Research Consortium-defined device succes

20 An Ahmed glaucoma valve (AGV; New World Medical) was implanted in 12 eyes,

21 Evolut R/PRO implantation in bicuspid aortic valve anatomy; a higher rate of moderate-severe paravalv

22 The first-generation Portico valve and delivery system did not offer advantages over

23 eplacement with the first generation Portico valve and delivery system or a commercially available va

24 core. EE more frequently involved the aortic valve and prosthesis (64.3% vs. 46.7%; p < 0.001; and 35

25 is the source of the cells that make up the valves and a portion of the coronary vasculature.

26 ences, EE more frequently affects prosthetic valves and less frequently pacemakers/defibrillators.

27 The integration of valves and pumps enables the complete removal of cell-fr

28 e rise to portions of the outflow tract, the valves and the arteries of the heart.

29 trial (The Placement of Aortic Transcatheter Valves) and registry the outcomes after aortic valve rep

30 ification of Rvol using valve tracking (Rvol(VALVE)), and semiautomated quantification of Rvol using

31 ormalities in the left ventricle, associated valves, and ascending aorta.

32 e of a highly reduced labiate process on its valve; and this evolutionary position is robustly suppor

33 gh data on the long-term durability of these valves are lacking.

34 SA) compared with any commercially available valves are needed to compare performance among designs.

35 (50.4% men; mean age, 77 years) with aortic valve area <1.3 cm(2) and analyzed the occurrence of all

36 Aortic valve area (AVA) <=1.0 cm(2) is a defining characteristi

37 out imaging demonstrated that smaller aortic valve area is predictive of increased risk for aortic va

38 Aortic valve area measurements were submitted to genome-wide as

39 onstructed a polygenic risk score for aortic valve area, which in a separate cohort of 311 728 indivi

40 h LF and NF groups had similar demographics, valve areas and indices.

41 causes a progressive narrowing of the aortic valve as a consequence of thickening and calcification o

42 conduit as the fixed effect of interest and valve as a fixed nuisance effect with post hoc pairwise

43 s of left-sided suspected IE (188 prosthetic valves/ascending aortic prosthesis and 115 native valves

44 ed survival free of surgery on the implanted valve at 10 years (Melody, 87%, versus SPVR, 87%; P=0.54

45 ve maladapts in those patients rendering the valve at least partially culpable for its dysfunction.

46 re frequent in transcatheter versus surgical valves at 30 days (13% vs. 5%; p = 0.03), but not at 1 y

47 performed by switching a couple of solenoid valves at branched outlets according to signals obtained

48 Patients with bicuspid aortic valve (AV) stenosis were excluded from the pivotal evalu

49 n form of heart disease involving the aortic valve (AV).

50 a novel technique for quantifying lymphatic valve back-leak.

51 Bicuspid aortic valve (BAV) is the most prevalent congenital heart defec

52 stribution, geologists have documented fault valving behavior, that is, cyclic changes in pressure an

53 and evaluated the prognostic value of aortic valve calcium score and biomarkers.

54 coronary artery, thoracic aorta, and cardiac valve calcium scores and pulse wave velocity were not si

55 tcomes and hemodynamic performance may guide valve choice in this cohort of patients undergoing trans

56 ] men, median age 62 years, 153 [66%] native valves) comprised 58 (25%) PVC results and 173 (75%) neg

57 s and Enterococcus spp. were associated with valve culture growth.

58 atment, the additional effect of preop-AT on valve culture results per 2-day interval was minor.

59 58 (25%) PVC results and 173 (75%) negative valve culture results.

60 nt with Tetralogy of Fallot, a serious heart valve defect, affects the substrate selectivity of ADAM1

61 thromboembolic complications and structural valve degeneration needs further assessment.

62 re replacement, catheter-based bioprosthetic valve deployment offers a minimally invasive treatment o

63 Definitions of structural valve deterioration (SVD), based on valve related reinte

64 base-case analysis, patients with structural valve deterioration requiring reoperation were assumed t

65 actor (HB-EGF), a crucial regulator of heart valve development in mice.

66 Heart valve development is regulated by complex interactions b

67 Superconductor(S)/Ferromagnet(F) pseudo spin-valve devices based on amorphous [Formula: see text] thi

68 a is predictive of increased risk for aortic valve disease (odds ratio, 1.14; P=2.3x10(-6)).

69 Database, we identified patients with aortic valve disease admitted 2012 to 2016 for SAVR, TAVR, and

70 links between the polygenic score for aortic valve disease and key health-related comorbidities invol

71 ly members presenting with progressive heart valve disease early in life.

72 Heart valve disease is a common manifestation of cardiovascula

73 m patients aged over 70 years who had mitral valve disease or atrial fibrillation when compared with

74 anch block may also develop following aortic valve disease or cardiac procedures.

75 HF (including ischemic heart disease, aortic valve disease, atrial fibrillation, congenital heart dis

76 o investigate the genetic etiology of aortic valve disease, perform clinical prediction, and uncover

77 , >=3 positive blood culture bottles, native valve disease, prosthetic valve, previous IE, and cardia

78 trial fibrillation, heart failure, and heart valve disease.

79 ailure, prior endocarditis, and degenerative valve disease; and had higher median age-adjusted Charls

80 -/-) mice, we tested our method on lymphatic valves displaying a wide range of dysfunction, from full

81 were varied to determine the impact of TAVR valve durability on life expectancy in a cohort of low-r

82 as conducted to determine the impact of TAVR valve durability on life expectancy in younger age group

83 However, the impact of transcatheter valve durability remains uncertain.

84 he basis of current evidence supporting TAVR valve durability.

85 eased in patients with more than mild aortic valve dysfunction but was independent from BAV leaflet f

86 int of view: When the shell is closed, the 2 valve edges meet each other in a commissure that forms a

87 dable Edwards-SAPIEN, SAPIEN XT, or SAPIEN 3 valve [Edwards LifeSciences, Irvine, CA, USA]; or a supr

88 delivery system or a commercially available valve (either an intra-annular balloon-expandable Edward

89 4), second valve implantation (P=0.013), and valve embolization (P=0.009) in the ER group.

90 f 18F-FDG-PET/CT for the diagnosis of native valve endocarditis (NVE).

91 In nonoperated prosthetic valve endocarditis (PVE), long-term outcome is largely u

92 IE particularly in the setting of prosthetic valve endocarditis, paravalvular extension of infection,

93 e diagnosis of device-related and prosthetic valve endocarditis, that addition has not been incorpora

94 At a transcatheter valve failure time <30% compared with surgical valves, S

95 prostatic hyperplasia or posterior urethral valves) focuses on symptoms.

96 l model to carry out longitudinal studies of valve formation and function.

97 To gain mechanistic understanding of cardiac valve formation at single-cell resolution and insights i

98 consequences of rs174547 in tricuspid aortic valves from patients with AS.

99 sessing the function of venous and lymphatic valves from various species, including humans.

100 Valve function at discharge was excellent in most patien

101 for the quantitative assessment of lymphatic valve function utilizes the servo-null micropressure sys

102 the surface of a giant magnetoresistive spin-valve (GMR SV) sensor using peptides.

103 At 30-day follow-up, median mean mitral valve gradient was 7 mm Hg, most patients (96.7%) had mi

104 e Portico valve group than in the commercial valve group (52 [13.8%] vs 35 [9.6%]; absolute differenc

105 ys, the event rate was higher in the Portico valve group than in the commercial valve group (52 [13.8

106 ortico group vs 48 [13.4%] in the commercial valve group; difference 1.5%, 95% CI -3.6 to 6.5 [UCB 5.

107 ugh patients treated with balloon-expandable valve had a higher rate of annular rupture.

108 cond-generation SAPIEN XT balloon-expandable valve has a higher 5-year rate of SVD, whereas the third

109 replacement using aortic transcatheter heart valves has recently become an alternative for patients w

110 duced leaflet motion of bioprosthetic aortic valves have been documented by four-dimensional computed

111 frame with no significant alteration of the valve housing.

112 ly lower for native valve IE than prosthetic valve IE and cardiac implantable electronic devices IE.

113 r, sensitivity was markedly lower for native valve IE than prosthetic valve IE and cardiac implantabl

114 II Trial: Placement of AoRTic TraNscathetER Valves II - High Risk and Nested Registry 7 [PII S3HR/NR

115 II Trial: Placement of AoRTic TraNscathetER Valves II - PARTNER II - PARTNERII - S3 Intermediate [PA

116 II Trial: Placement of AoRTic TraNscathetER Valves II - PARTNER II - PARTNERII - S3 Intermediate [PA

117 The value of CT for catheter-delivered valve implantation (eg, transcatheter aortic and mitral

118 nificant paravalvular leak (P=0.004), second valve implantation (P=0.013), and valve embolization (P=

119 Percutaneous pulmonary valve implantation (PPVI) has become an important treatm

120 mboembolic events after transcatheter aortic-valve implantation (TAVI) in patients who do not have an

121 Transcatheter aortic valve implantation (TAVI) still presents complications:

122 Transcatheter mitral valve implantation (TMVI) is emerging as an alternative

123 sfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) registry retrospectively in

124 icular Remodeling After Transcatheter Aortic Valve Implantation [RASTAVI]; NCT03201185).

125 al characteristics were collected, including valve implantation depth and membranous septum length, a

126 Nine patients had a second valve implanted.

127 llow-up after TAVI with a balloon-expandable valve in 3.5% of patients and was successful in all pati

128 intracardiac connections, with the tricuspid valve in the normal position and normal size of the left

129 , 40%, and 50% shorter than that of surgical valves in 40-, 50-, and 60-year-old patients, respective

130 Three valve-in-ring patients required the implantation of a se

131 Valve-in-valve (VIV) transcatheter aortic valve replacem

132 uiring reoperation were assumed to undergo a valve-in-valve TAVR procedure.

133 ents underwent surgical valve replacement or valve-in-valve TPVR.

134 d phenotypic changes occurring in the aortic valve interstitial cells (VICs) during osteogenic differ

135 All patients had pre-valve intervention 6MWT, echocardiography and CMR with 4

136 n in future trials to determine if tricuspid valve intervention improves outcomes in this high-risk g

137 The mitral valve is a complex structure with a three-dimensional sa

138 The aortic valve is an important determinant of cardiovascular phys

139 sed method, the competence of each lymphatic valve is challenged over a physiological range of pressu

140 ortic balloon-expandable transcatheter heart valves is associated with a low complication rate, a 30-

141 nd that the opening and closing of lymphatic valves leads to significant changes in axial strain thro

142 Aortic valve leaflet fusion pattern and sex were not associated

143 f thickening and calcification of the aortic valve leaflets.

144 Americans suffer from significant tricuspid valve leakage.

145 Mitral regurgitation (MR) is a complex valve lesion that can pose significant management challe

146 we set out to demonstrate that the tricuspid valve maladapts in disease.

147 paradigm and hypothesize that the tricuspid valve maladapts in those patients rendering the valve at

148 nt-Adamts19-Klf2 axis is required for proper valve maturation and maintenance.

149 expanding CoreValve, Evolut-R, or Evolut-PRO valve [Medtronic, Minneapolis, MN, USA]).

150 ival with the originally implanted pulmonary valve (Melody group, 80%; SPVR group, 73%; P=0.46) betwe

151 time that VEGF-C signaling is necessary for valve morphogenesis.

152 large pediatric cohort of patients with BAV, valve morphology, AS, and AI are independently associate

153 , patients suffering from posterior urethral valves (n = 49), spina bifida (n = 21), central neurogen

154 expression was slightly lower in the mitral valves of MVP patients treated with MRA.

155 cterial growth in cultures of resected heart valves of patients with infective endocarditis (IE) is i

156 ndocarditis (IE) in patients with prosthetic valves or implantable devices.

157 ups experienced improvement of symptoms, and valve performance remained stable.

158 Clinical outcomes and valve performance were assessed up to 2 years after the

159 improved procedural safety and bioprosthetic valve performance.

160 II Trial: Placement of AoRTic TraNscathetER Valves - PII A [PARTNERII A]; NCT01314313; The PARTNER I

161 Ahmed(C) (FP7 or FP8) valve placement (8 eyes) had 25% success rate with 1.7 +

162 Advanced imaging planning, new transcatheter valve platforms, procedure streamlining and growing oper

163 Secondary valves prevent reflux and allow for the generation of pr

164 re bottles, native valve disease, prosthetic valve, previous IE, and cardiac device.

165 Mitral valve prolapse (MVP) is often considered benign but rece

166 spitalization for heart failure symptoms and valve prosthesis complication; or (3) stroke.

167 10 between TAVR and SAVR until transcatheter valve prosthesis failure time was 70% shorter than that

168 The pulmonary valve (PV) is of primary concern because of its involvem

169 nt of variation = 27%) and moderate for Rvol(VALVE) (r = 0.72, coefficient of variation = 57%).

170 tients with BPVT had a higher probability of valve re-replacement (68% vs. 24% at 10 years' post-BPVT

171 from 39 patients in sinus rhythm with mitral valve regurgitation (group 2; 32 males; 59+/-12 years).

172 ned for treatment of postoperative pulmonary valve regurgitation in patients with repaired right vent

173 mixed lesion with moderate/severe pulmonary valve regurgitation).

174 icant serositis and severe mitral and aortic valve regurgitation, controlled with adalimumab, tacroli

175 TMVr) with MitraClip in patients with mitral valve regurgitation.

176 of procedural secondary outcomes (eg, aortic valve reintervention, pacemaker rates) were more closely

177 ructural valve deterioration (SVD), based on valve related reintervention or death, underestimate the

178 influences outcomes of transcatheter mitral valve repair (TMVr) in patients with HF with SMR.

179 tral regurgitation with transcatheter mitral valve repair (TMVr) using the MitraClip plus guideline-d

180 ealth status benefit of transcatheter mitral valve repair (TMVr) with MitraClip in patients with mitr

181 l Regurgitation) trial, transcatheter mitral valve repair (TMVr) with the MitraClip rapidly improved

182 A strategy of initial aortic valve repair followed by delayed Ross procedure may prov

183 Valve repair is preferable over replacement for rheumati

184 Surgical valve repair or replacement has been the standard of car

185 ne-directed medical therapy, surgical mitral valve repair or replacement, and, in the setting of adva

186 Transcatheter mitral valve repair with the MitraClip results in marked clinic

187 bitors, vericiguat, and transcatheter mitral valve repair, all of which incrementally improve prognos

188 guiding the procedure (mitral and tricuspid valve repair, left atrial appendage closure, and paraval

189 ation; coronary artery bypass surgery; heart valve repair/replacement; percutaneous coronary interven

190 erior and may be superior to surgical aortic valve replacement (SAVR) for mortality, stroke, and reho

191 a reasonable alternative to surgical aortic valve replacement (SAVR) for patients with severe aortic

192 severe aortic stenosis after surgical aortic valve replacement (SAVR) or transcatheter aortic valve r

193 replacement (TAVR) and redo surgical aortic valve replacement (SAVR) represent the 2 treatments for

194 Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) and redo surgical aortic valve

195 sist device (LVAD), and transcatheter aortic valve replacement (TAVR) are expensive cardiovascular te

196 tion disturbances after transcatheter aortic valve replacement (TAVR) has been elusive.

197 Transcatheter aortic valve replacement (TAVR) has emerged as a reasonable alt

198 The role of transcatheter aortic valve replacement (TAVR) in this high-risk population is

199 ial results showed that transcatheter aortic valve replacement (TAVR) is noninferior and may be super

200 e these phenomena after transcatheter aortic-valve replacement (TAVR) is not known.

201 mboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear.

202 The effect of transcatheter aortic valve replacement (TAVR) on kidney function stage in pat

203 0 days and 1 year after transcatheter aortic valve replacement (TAVR) or surgery.

204 Two competing transcatheter aortic valve replacement (TAVR) technologies are currently avai

205 ding the indication for transcatheter aortic valve replacement (TAVR) to low-risk patients with sympt

206 Transcatheter aortic valve replacement (TAVR) use is increasing in patients w

207 tic stenosis undergoing transcatheter aortic valve replacement (TAVR).

208 e replacement (SAVR) or transcatheter aortic valve replacement (TAVR).

209 dmission is common post-transcatheter aortic valve replacement (TAVR).

210 ical explantation after transcatheter aortic valve replacement (TAVR).

211 results in futility of transcatheter aortic valve replacement (TAVR).

212 y affect patients after transcatheter aortic valve replacement (TAVR).

213 alizations 1 year after transcatheter aortic valve replacement (TAVR).

214 Transcatheter pulmonary valve replacement (TPVR) is associated with a risk of pr

215 dney injury early after transcatheter aortic valve replacement and is an independent predictor of 30-

216 ings may have implications for the timing of valve replacement and the role of adjunctive medical the

217 cation for transfemoral transcatheter aortic valve replacement as agreed by the heart team were rando

218 893 patients undergoing transcatheter aortic valve replacement at 445 hospitals were analyzed.

219 re commonly reported in transcatheter aortic valve replacement clinical trials.

220 13, relative to baseline trends, the odds of valve replacement decreased by 4.0% per quarter (odds ra

221 their risk of reaching a clinical end point (valve replacement for symptoms, hospitalization, or card

222 ted patients undergoing transcatheter aortic valve replacement from November 1, 2011 to June 30, 2016

223 vidual end points after transcatheter aortic valve replacement has been conducted to date.

224 AVI trials (Surgical or Transcatheter Aortic Valve Replacement in Intermediate-Risk Patients) to 100%

225 ar atrial fibrillation; transcatheter aortic valve replacement in patients with symptomatic severe ao

226 merging as an alternative to surgical mitral valve replacement in selected high-risk patients.

227 In patients undergoing transcatheter aortic valve replacement in the US, vascular complications and

228 tic valve replacement versus surgical aortic valve replacement in the whole cohort and within each fl

229 Although aortic valve replacement is associated with a major benefit in

230 lves) and registry the outcomes after aortic valve replacement of the 4 flow-gradient groups.

231 nd 17 additional patients underwent surgical valve replacement or valve-in-valve TPVR.

232 ra-large aortic annuli, transcatheter aortic valve replacement using 29-mm Sapien-3 and 34-mm ER is s

233 Transcatheter mitral valve replacement using aortic transcatheter heart valve

234 clinical events between transcatheter aortic valve replacement versus surgical aortic valve replaceme

235 aortic annuli underwent transcatheter aortic valve replacement with 29-mm Sapien-3 (n=640) or 34-mm E

236 cular access method, to transcatheter aortic valve replacement with the first generation Portico valv

237 There were 47 primary end points (41 valve replacement, 1 death, and 5 hospitalizations-1 che

238 s with severe symptomatic AS awaiting aortic valve replacement, there has been a trend of increasing

239 ed of a total of 22 876 referrals for aortic valve replacement, with (N=8098) TAVR and (N=14 778) SAV

240 to lung transplant via transcatheter aortic valve replacement.

241 s many of the risks associated with surgical valve replacement.

242 (RBC) transfusion after transcatheter aortic valve replacement.

243 independently associated with repeat mitral valve replacement.

244 ransplant 56 days after transcatheter aortic valve replacement.

245 of CT-FFR for coronary evaluation pre-aortic valve replacement.

246 bstruction required elective surgical mitral valve replacement.

247 were both associated with a need for repeat valve replacement.

248 of patients undergoing transcatheter aortic valve replacement.

249 ents after transfemoral transcatheter aortic valve replacement; propensity score-matching identified

250 ntation (eg, transcatheter aortic and mitral valve replacements) was further elucidated in large-coho

251 hain reaction with sequencing on a different valve sample.

252 lve failure time <30% compared with surgical valves, SAVR was the preferred option.

253 gaps or overlaps despite the fact that each valve, secreted by 2 mantle lobes, may present antisymme

254 Polymeric heart valves seem to be an attractive alternative to mechanica

255 l defects in the endocardial-derived cardiac valve, septum, and vasculature.

256 his ex vivo modeling system, clinically used valve-sparing aortic root replacement conduit configurat

257 graft configurations are clinically used for valve-sparing aortic root replacement, some specifically

258 Aortic valve stenosis (AVS), which is the most common valvular

259 04 [95% CI, 0.77-1.39]; P=0.810), and aortic valve stenosis (OR, 1.03 [95% CI, 0.56-1.90]; P=0.926).

260 subjects with a medical diagnosis of aortic valve stenosis (remaining n=308 683 individuals), phenom

261 ssociated with causal risk ratios for aortic valve stenosis and replacement, respectively, of 1.52 (9

262 x is causally associated with risk of aortic valve stenosis and replacement.

263 lly associated with increased risk of aortic valve stenosis.

264 t in patients with symptomatic severe aortic valve stenosis; and antiplatelet agents vorapaxar and pr

265 EDV) E/A ratio and 4D flow derived tricuspid valve stroke volume demonstrated independent association

266 ter coronary artery bypass grafting + mitral valve surgery (1.38; 95% CI, 1.11-1.70).

267 2.18; 95% CI, 1.71-2.77) and mitral + aortic valve surgery (1.85; 95% CI, 1.33-2.58) and lowest after

268 e subset of patients who underwent tricuspid valve surgery (n = 344), a post-operative improvement in

269 oss procedure performed after initial aortic valve surgery achieves superior long-term survival and f

270 Timely heart valve surgery can mitigate the progression to heart fail

271 In IE cases treated with valve surgery, Staphylococcus aureus and Enterococcus sp

272 r a secondary operation after initial aortic valve surgery.

273 ive Risk Evaluation and more often underwent valve surgery.

274 FLD-bioassay-RP-HPLC-UV/vis-ESI(-)-MS with a valve switch and NP-HPLC-UV/vis/FLD-bioassay-RP/IEX-HPLC

275 ion mode (ESI(-)), an RP-18e-HPLC column and valve switch were exploited.

276 g intra-annular Portico transcatheter aortic valve system (Abbott Structural Heart, St Paul, MN, USA)

277 here, a programmable epidermal microfluidic valving system is devised, which is capable of biofluid

278 g of open circulatory systems, have flexible valving systems between thorax and abdomen that can sepa

279 operation were assumed to undergo a valve-in-valve TAVR procedure.

280 include a torus-margo structure acting as a valve that prevents air from spreading between tracheids

281 Stomata are epidermal valves that facilitate gas exchange between plants and t

282 For patients with severely impacted aortic valves that require replacement, catheter-based bioprost

283 se for many decades, but transcatheter heart valve therapy has revolutionized the field in the past 1

284 ber 2013 and March 2019 in the Transcatheter Valve Therapy Registry were included.

285 American College of Cardiology Transcatheter Valve Therapy Registry, we evaluated patients undergoing

286 American College of Cardiology Transcatheter Valve Therapy Registry.

287 rdial infarction, stroke, aortic dissection, valve thrombosis, endocarditis, and urgent cardiac inter

288 ata on the durability of transcatheter heart valves (THVs) are limited.

289 with self expanding (SE) transcatheter heart valves (THVs) on individual end points after transcathet

290 The Harmony transcatheter pulmonary valve (TPV) was designed for treatment of postoperative

291 rwent surgical valve replacement or valve-in-valve TPVR.

292 , semiautomated quantification of Rvol using valve tracking (Rvol(VALVE)), and semiautomated quantifi

293 derived MV regurgitation quantification than valve tracking in terms of agreement with indirect quant

294 Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR

295 UFA incorporation into human stenotic aortic valves was higher in noncalcified regions compared with

296 P/IEX-HPLC), UV/vis detector, and a Rheodyne valve were installed between the zone eluting interface

297 hort available, we observed that Sapien 3 BE valves were associated with lower rates of all-cause dea

298 s/ascending aortic prosthesis and 115 native valves) were studied.

299 tients required the implantation of a second valve, which led to an overall procedural success rate o

300 It is unknown whether transcatheter valves will have similar durability as surgical bioprost